Retrospective, multicenter analysis of the safety and effectiveness of direct oral anticoagulants for the treatment of venous thromboembolism in obesity.

Jeffrey D SperryAletha LoebMelissa J SmithTessa B BrightonJulie A EhretJoli D FermoMorgan E GentiliJason W LancasterJennifer N MazurKatherine SpezzanoJennifer A Szwak

Published in: Journal of thrombosis and thrombolysis (2024)

There was no significant difference in VTE recurrence or major bleeding related to BMI among patients treated with DOACs. This study showed that DOACs may be a safe and effective VTE treatment option in patients with obesity.

Keyphrases

venous thromboembolism
direct oral anticoagulants
atrial fibrillation
metabolic syndrome
insulin resistance
type diabetes
weight loss
weight gain
systematic review
body mass index
clinical trial